Bladder Small Cell Neuroendocrine Carcinoma
NCI Definition: A highly aggressive carcinoma, histologically resembling small cell lung carcinoma. In most cases it is associated with carcinoma in situ. 
Bladder small cell neuroendocrine carcinomas most frequently harbor alterations in TP53, RB1, CREBBP, KMT2D, and FGFR1 .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, TP53 Exon 5 Mutation, and TP53 Exon 7 Mutation are the most common alterations in bladder small cell neuroendocrine carcinoma .
There are 8 clinical trials for bladder small cell neuroendocrine carcinoma, of which 5 are open and 3 are completed or closed. Of the trials that contain bladder small cell neuroendocrine carcinoma as an inclusion criterion, 3 are phase 1 (3 open) and 5 are phase 2 (2 open).
Ipilimumab, nivolumab, and aldesleukin are the most common interventions in bladder small cell neuroendocrine carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.